1 withdrawn. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
Follow CLL: new trials by email Literature Review of CLL trials Research Report on CLL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL Dose combination 1-1, dose combination 1-2, Dose combination 1-3 - Chronic Lymphocytic Leukemia, CLL | Phase 1 | Withdrawn | Virginia Commonwealth University | 2020-10-02 | 2021-11-09 |
Leukemia, Lymphocytic, Chronic, B-Cell (1)
Chronic Disease (1) · Disease Attributes (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Lymphoid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Virginia Commonwealth University (1)